# ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer

> **NCT07423611** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 388 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Aromatase inhibitor (± ovarian suppression) plus Ribociclib
- **DRUG:** 4 cycles of TC (docetaxel + cyclophosphamide) adjuvant chemotherapy

## Key facts

- **NCT ID:** NCT07423611
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10-01
- **Primary completion:** 2030-10-01
- **Final completion:** 2030-12-31
- **Target enrollment:** 388 (ESTIMATED)
- **Last updated:** 2026-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07423611

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07423611, "ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT07423611. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*